フェトロージャ点滴静注用 1g

第 2 部 (モジュール 2) : CTD の概要 (サマリー)

2.7 臨床概要

2.7.5 参考文献

塩野義製薬株式会社

目次

2.7.5 参考文献 3

2.7.5 参考文献

2.7.1 参考文献

なし

2.7.2 参考文献

1. 厚生労働省医薬・生活衛生局医薬品審査管理課. 医薬品開発と適正な情報提供のための薬物相互作用ガイドライン. 平成 30 年 7 月 23 日.
2. Boselli E, Breilh D, Rimmelé T, et al. Plasma and lung concentrations of ceftazidime administered in continuous infusion to critically ill patients with severe nosocomial pneumonia. Intensive Care Medicine 2004;30(5):989-91.
3. CEPTAZ® ceftazidime for injection Product Information 29 March 2002 available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2002/050646s014lbl.pdf. Accessed: January 2019.CLSI, Oct 2008.
4. 厚生労働省医薬食品局審査管理課長. 非抗不整脈薬における QT/QTc 間隔の延長と催不整脈作用の潜在的可能性に関する臨床的評価ガイドライン. 平成 21 年 10 月 23 日.
5. Craig WA, Suh B. Protein binding and the antimicrobial effects: methods for the determination of protein binding. Antibiotics in laboratory medicine 1986; 477–517.
6. Kiem S, Schentag JJ. Interpretation of antibiotic concentration ratios measured in epithelial lining fluid. Antimicrob Agents Chemother 2008; 52(1):24-36.
7. Lamer C, De Beco V, Soler P, et al. Analysis of vancomycin entry into pulmonary lining fluid by bronchoalveolar lavage in critically ill patients. Antimicrob Agents Chemother 1993; 37(2):281-6.
8. Bullen JJ. The significance of iron in infection. Rev Infect Dis 1981;3:1127-38.
9. Jurado RL. Iron, infections, and anemia of inflammation. Clin Infect Dis 1997;25(4):888-95.
10. Buchanan SK. Bacterial metal detectors. Mol Microbiol 2005;58(5):1205-9.
11. Livermore DM. Current epidemiology and growing resistance of gram-negative pathogens. Korean J Intern Med 2012;27(2):128-42.
12. Curtis NA, Eisenstadt RL, East SJ, et al. Iron-regulated outer membrane proteins of *Escherichia coli* K-12 and mechanism and action of catechol-substituted cephalosporins. Antimicrob Agents Chemother 1988;32(12):1879-86.
13. Krewulak KD, Vogel HJ. Structural biology of bacterial iron uptake. Biochim Biophys Acta 2008;1778(9):1781-804.
14. Morrissey I, Hackel M, Badal R, Bouchillon S, Hawser S, Biedenbach D. A review of ten years of the Study for Monitoring Antimicrobial Resistance Trends (SMART) from 2002 to 2011. Pharmaceuticals (Basel) 2013;6(11):1335-46.
15. Colpan A, Johnston B, Porter S, et al. *Escherichia coli* sequence type 131 (ST131) subclone H30 as an emergent multidrug-resistant pathogen among US veterans. Clin Infect Dis 2013;57(9):1256-65.
16. Tomaras AP, Crandon JL, McPherson CJ, et al. Adaptation-based resistance to siderophore-conjugated

antibacterial agents by *Pseudomonas aeruginosa*. Antimicrob Agents Chemother 2013; 57(9):4197-207.

17. Kim A, Kutschke A, Ehmann DE, et al. Pharmacodynamic profiling of a siderophoreconjugated monocarbam in *Pseudomonas aeruginosa*: Assessing the risk for resistance and attenuated efficacy. Antimicrob Agents Chemother 2015;59(12):7743-52.
18. Ito A, Nishikawa T, Ishii R, et al. Mechanism of Cefiderocol high MIC mutants obtained in non-clinical FoR studies. Open Forum Infect Dis; 2018 Nov 5 (Supp 1): S251.
19. CLSI. Summary Minutes Subcommittee on Antimicrobial Susceptibility Testing. Tempe Arizona, Clinical and Laboratory Standards Institute, 2016.
20. 国立感染症研究所薬剤耐性研究センター，国立感染症研究所感染症疫学センター，全国地方衛生研究所．カルバペネム耐性腸内細菌科細菌（carbapenem-resistant Enterobacteriaceae: CRE）病原体サーベイランス，2017 年．Infectious Agents Surveillance Report. 2018;39(9):162-3.
21. Shibata N, Doi Y, Yamane K, et al. PCR typing of genetic determinants for metallo-beta-lactamases and integrases carried by Gram-negative bacteria isolated in Japan, with focus on the class 3 integron. J Clin Microbiol 2003;41(12):5407–13.
22. Shields RK, Chen L, Cheng S, et al. Emergence of Ceftazidime-Avibactam Resistance Due to Plasmid-Borne blaKPC-3 Mutations during Treatment of Carbapenem-Resistant Klebsiella pneumoniae Infections. Antimicrob Agents Chemother 2017;61(3):e02097-16.
23. Dunne WM, Hardin DJ. Use of several inducer and substrate antibiotic combinations in a disk approximation assay format to screen for AmpC induction in patient isolates of *Pseudomonas aeruginosa*, Enterobacter spp., Citrobacter spp., and Serratia spp. J Clin Microbiol 2005;43(12):5945-9.
24. Huang H, Hancock RE. Genetic definition of the substrate selectivity of outer membrane porin protein OprD of *Pseudomonas aeruginosa*. J Bacteriol 1993;175(24):7793-800.
25. Zamorano L, Moyá B, Juan C, et al. Differential beta-lactam resistance response driven by ampD or dacB (PBP4) inactivation in genetically diverse *Pseudomonas aeruginosa* strains. J Antimicrob Chemother 2010;65(7):1540-2.
26. Leoni L, Orsi N, Lorenzo V, et al. Functional Analysis of PvdS, an Iron Starvation Sigma Factor of *Pseudomonas aeruginosa*. J Bacteriol 2000;182(6):1481-91.
27. Jordan LD, Zhou Y, Smallwood CR. Energy-dependent motion of TonB in the Gram-negative bacterial inner membrane. Proc Natl Acad Sci U S A 2013; 110(28): 11553-8.
28. Slauch JM, Garrett S, Jackson DE, et al. EnvZ functions through OmpR to control porin gene expression in *Escherichia coli* K-12. J Bacteriol 1988;70(1):439-41.
29. Nishino K, Nikaido E, Yamaguchi A. Regulation of multidrug efflux systems involved in multidrug and metal resistance of *Salmonella enterica* serovar Typhimurium. J Bacteriol 2007;189(24):9066-75.
30. Evans BA, Amyes SGB. OXA β-Lactamases. Clin Microbiol Rev 2014;7(2):241-63.
31. Zmarlicka MT, Nailor MD, Nicolau DP. Impact of the New Delhi metallo-beta-lactamase on beta-lactam antibiotics. Infect Drug Resist 2015;8:297-309.

2.7.3 参考文献

1. European Medicine Agency. Addendum to the guideline on the evaluation of medicinal products indicated for treatment of bacterial infections. Committee for Human Medicinal Products (CHMP). 24 October 2013 EMA/CHMP/351889/2013.
2. Nicolle LE, Bradley S, Colgan R, Rice JC, Schaeffer A, Hooton TM. Infectious Diseases Society of America Guidelines for the diagnosis and treatment of asymptomatic bacteriuria in adults. Clin Infect Dis 2005;40(5):643–54.
3. Craig WA. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin Infect Dis 1998;26(1):1-10.
4. Levison ME, Levison JH. Pharmacokinetics and pharmacodynamics of antibacterial agents. Infect Dis Clin North Am 2009;23(4):791-815.
5. Udy AA, Roberts JA, Shorr AF, Boots RJ, and Lipman J. Augmented renal clearance in septic and traumatized patients with normal plasma creatinine concentrations: identifying at-risk patients. Crit Care 2013;17(1):R35, 1-9.
6. Jacoby GA. AmpC beta-lactamases. Clin Microbiol Rev 2009;22(1):161–82.
7. Lahiri SD, Johnstone MR, Ross PL, McLaughlin RE, Olivier NB, Alma RA. Avibactam and class C β-lactamases: mechanism of inhibition, conservation of the binding pocket, and implications for resistance. Antimicrob Agents Chemother 2014;58(10):5704–13.

2.7.4 参考文献

1. Owens RC, Jr. An overview of harms associated with beta-lactam antimicrobials: where do the carbapenems fit in? Crit Care 2008;12 Suppl 4:S3.
2. 厚生労働省医薬食品局審査管理課長. 非抗不整脈薬における QT/QTc 間隔の延長と催不整脈作用の潜在的可能性に関する臨床的評価ガイドライン. 平成 21 年 10 月 23 日.
3. Sutter R, Rüegg S, Tschudin-Sutter S. Seizures as adverse events of antibiotic drugs: a systematic review. Neurology 2015; 85.15: 1332-41.
4. Alqahtani SA, Kleiner DE, Ghabril M, et al. Identification and characterization of cefazolin-induced liver injury. Clin Gastroenterol Hepatol 2015;13.7:1328-36.
5. Shearer MJ, Bechtold H, Andrassy K, et al. Mechanism of cephalosporin-induced hypoprothrombinemia: relation to cephalosporin side chain, vitamin K metabolism, and vitamin K status. J Clin Pharmacol 1988;28(1):88-95.
6. Sattler FR, Weitekamp MR, Ballard JO. Potential for bleeding with the new beta-lactam antibiotics. Ann Intern Med 1986;105(6):924-31.
7. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) Center for Biologics Evaluation and Research (CBER). Guidance for Industry Drug-Induced Liver Injury: Premarketing Clinical Evaluation. July 2009.
8. Loo AS, Gerzenshtein L, Ison MG. Antimicrobial drug-induced thrombocytopenia: a review of the literature. In: Seminars in thrombosis and hemostasis. Thieme Medical Publishers 2012: 818-29.

9. Wilson BR, Bogdan AR, Miyazawa M, Hashimoto K, Tsuji Y. Siderophores in iron metabolism: from mechanism to therapy potential. Trends Mol Med 2016;22(12):1077-90.
10. 厚生労働省医薬・生活衛生局医薬品審査管理課. 医薬品開発と適正な情報提供のための薬物相互作用ガイドライン. 平成 30 年 7 月 23 日.
11. Guideline on the investigation of drug interactions. CPMP/EWP/560/95/Rev.1 Corr.2. June 2012.